The cannabinoids, and what science actually knows

One honest thread runs through all of this: outside of CBD for specific seizure disorders, most cannabinoid “benefit” claims rest on cell, animal, or small early human studies, not the large, replicated trials that would make them proven therapies. We’ll flag the evidence level on each. Educational information, not medical advice.

• Δ9

  THC

  Well‑studied

  The main intoxicating compound: the classic “high,” from binding CB1 in the brain. Georgia now caps THC by total milligrams (the old 5% cap ended in 2026).

  The best‑characterized cannabinoid, for benefits and harms. There is real clinical evidence for chemo nausea, appetite, and neuropathic pain / MS spasticity. It also comes with well‑documented downsides: impairment, anxiety at higher doses, and dependence risk.

• CBD

  CBD

  FDA‑approved use

  The most abundant non‑intoxicating cannabinoid. No “high,” widely sold in wellness products.

  The one cannabinoid with gold‑standard evidence for a specific use: the purified drug Epidiolex is FDA‑approved for certain seizure disorders. Everything else (sleep, anxiety, pain) is far weaker and mostly small or mixed studies. It can also interact with other medications.

• CBG

  CBG

  Preclinical

  The non‑intoxicating “mother cannabinoid.” Its acid form is what the plant turns into THC, CBD, and CBC. Usually present in small amounts.

  Almost entirely preclinical. Lab and animal work suggests anti‑inflammatory, neuroprotective, even antibacterial activity, but human data are very sparse. “CBG for focus/gut” claims run well ahead of the evidence.

• CBN

  CBN

  Weak / mixed

  A mildly‑ or non‑intoxicating cannabinoid formed as THC ages. Heavily marketed in “sleep” products.

  The “CBN = sleep aid” idea long rested on old, confounded observations of aged, sedating cannabis. A large 2024 randomized trial did find oral CBN (25–100mg) improved self‑reported sleep over placebo, about on par with melatonin. But it was funded by a CBN maker and used sleep questionnaires, not objective sleep‑lab measures, so it is promising rather than settled. Treat sleep marketing with healthy skepticism.

• CBC

  CBC

  Preclinical

  A non‑intoxicating minor cannabinoid, one of the four the plant most commonly makes. Typically low concentrations.

  Preclinical only. Cell and animal studies point to anti‑inflammatory, pain‑reducing, and neuroprotective activity, but there is essentially no controlled human evidence yet.

• THCV

  THCV

  Early research

  Structurally related to THC. Largely non‑intoxicating at low doses; mildly psychoactive higher up. Marketed for appetite/energy.

  Early. The “appetite suppressant / diet weed” idea comes mainly from rodent studies where it blocked CB1 and reduced food intake. It is a genuinely interesting research candidate for obesity and diabetes, though not a proven appetite suppressant.

• THCA

  THCA

  Preclinical

  The raw, acidic precursor in the living plant. NOT intoxicating on its own, but heat (smoking, vaping) converts it into intoxicating THC.

  Preclinical, with a practical catch: raw THCA doesn’t get you high, but a vaporizer turns it into THC. Lab/animal hints at anti‑inflammatory and anti‑nausea activity; minimal human data. (Labs often report “total THC” to account for this conversion.)

• CBDA

  CBDA

  Preclinical

  The raw, acidic precursor to CBD. Non‑intoxicating; heat converts it into CBD.

  Preclinical. Some lab work suggests it may be more potent than CBD at certain targets and absorb better than once thought, but that’s animal/mechanistic work, not proven human therapy.

• Δ8

  Delta‑8

  Caution

  A THC isomer, mildly intoxicating, often pitched as a “milder high.” Most on the market is chemically converted from hemp CBD, not extracted from the plant.

  The headline here is simple: legally gray and under‑studied. It rode a hemp‑law loophole and is sold with little oversight, and the FDA has flagged adverse events, poison‑control calls, and contaminated, inconsistent products from unregulated synthesis. Approach with caution.

Science reviewed against current research · Jul 27, 2026

Educational only. This is not medical or dosing advice. Talk to your Georgia physician about your care.